Overview

Neuralink is the most publicly visible commercial BCI company, pursuing direct brain implants through minimally invasive robotic insertion. Founded in 2016 with backing from CEO Elon Musk, the company has raised over $1 billion in funding, including a $650 million Series E round in June 2025, reaching a reported valuation of approximately $9 billion.

Technical Approach

The N1 implant contains 1,024 electrodes distributed across a Utah Array-based design, enabling simultaneous recording from thousands of neurons. Neuralink developed proprietary robotic surgical equipment to precisely position the electrode array in the motor cortex through a small burr hole, reducing surgical complexity compared to traditional open-brain procedures.

Clinical Progress

Neuralink’s PRIME study (Primary Inhibition of Motor Neuron Excitability) has enrolled 21+ human participants. The company received FDA Breakthrough Device Designation, accelerating its regulatory pathway. Initial patients have demonstrated functional control of prosthetic limbs and computer cursors through neural signals. The company is advancing toward broader clinical applications in spinal cord injury and motor neuron disease.

Competitive Position

Neuralink’s combination of high electrode count, automated implantation robotics, and aggressive funding timeline positions it as the leading contender in the race toward high-bandwidth brain-computer interfaces for paralyzed patients.